Table 2. Effects of Radotinib on the cell viability in patients with AML and CML.

UPN	Disease	Cell source	0 μM	1 μM	10 μM	100 μM
1	AML	BM	100 ± 0.0	69 ± 1.2 ***	58± 1.5 ***	57 ± 2.3 ***
2	AML	BM	100 ± 0.0	75 ± 1.0 ***	73 ± 0.5 ***	68 ± 0.9 ***
3	AML	BM	100 ± 0.0	85 ± 2.5 ***	78 ± 2.5 ***	65 ± 2.7 ***
4	AML	BM	100 ± 0.0	103 ± 6.5	64 ± 6.2 ***	45 ± 3.5 ***
5	AML	BM	100 ± 0.0	95 ± 0.9 **	90 ± 0.9 ***	78 ± 2.1 ***
6	AML	PB	100 ± 0.0	91 ± 3.9	86 ± 6	87 ± 3 *
7	AML	PB	100 ± 0.0	94 ± 0.6 **	90 ± 0.8 **	69 ± 1.8 ***
8	CML	BM	100 ± 0.0	98 ± 7.8	88± 3.7	87 ± 6.3
9	CML	BM	100 ± 0.0	91 ± 5.5	95 ± 9.2	77 ± 2.9 **
10	CML	BM	100 ± 0.0	96 ± 0.6	100 ± 1	112 ± 2
11	CML	BM	100 ± 0.0	99 ± 0.8	102 ± 0.4	113 ± 1
12	CML	PB	100 ± 0.0	101 ± 3.2	98 ± 1.4	91 ± 5

These data represent the means ± SEM. Significantly different from control, 0 μM (*);

*: P < 0.05;

**: P < 0.01;

***: P < 0.001.